Sep 30, 2019   SOURCE: PR NewsWire

Synthetic Lethality-based Drugs and Targets Market, 2030

DUBLIN, Sept. 30, 2019 /PRNewswire/ -- The "Synthetic Lethality-based Drugs and Targets Market, 2019-2030: Focus on DNA Repair (including PARP Inhibitors) and Other Novel Cellular Pathways" report has been added to ResearchAndMarkets.com's offering.

https://mma.prnewswire.com/media/539438/Research_and_Markets_Logo.jpg

The Synthetic Lethality-based Drugs and Targets Market, 2019-2030: Focus on DNA Repair (including PARP Inhibitors) and Other Novel Cellular Pathways' report features an extensive study of the current market landscape and the future potential of the synthetic lethality-based therapeutics. It features an in-depth analysis, highlighting the capabilities of various companies engaged in this domain.

Currently, there are four approved (and marketed) poly-ADP ribose polymerase (PARP) inhibitor drugs, which have been shown to operate based on the concept of synthetic lethality. Further, several such drugs are being investigated for the treatment of a myriad of advanced oncological and non-oncological indications. A number of companies are engaged in this domain; moreover, both venture capital (VC) firms and government bodies are actively funding such research initiatives.

One of the key objectives of the report was to estimate the existing market size and identify the future opportunity for synthetic lethality-based drugs, over the next decade. Based on multiple parameters, such as target consumer segments, region-specific disease prevalence, anticipated adoption of the marketed and late stage drugs and the likely selling price, we have provided informed estimates on the evolution of the market over the period 2019-2030. The report includes potential sales forecast of drugs that are currently marketed or are in late stages of development (phase II and above).

The report also features the likely distribution of the current and forecasted opportunity across 

    --  [A] type of molecules (small molecule and biologic)
    --  [B] different target indications (breast cancer, colorectal cancer,
        fallopian tube cancer, gastric cancer, head and neck cancer, lung
        cancer, ovarian cancer, peritoneal cancer and others)
    --  [C] synlet targets (APE1 / Ref-1, Chk1, GLS1, PARP, Pol , PP2A and Wee1)
    --  [D] route of administration (oral and intravenous)
    --  [E] key geographical regions (North America, EU5, Asia-Pacific and Rest
        of the World).

Key Topics Covered:

1 PREFACE
1.1. Scope of the Report
1.2. Research Methodology
1.3. Chapter Outlines

2 EXECUTIVE SUMMARY

3 INTRODUCTION TO DNA DAMAGE AND REPAIR SYSTEMS
3.1. Chapter Overview
3.2. Overview of Deoxyribonucleic Acid (DNA) Damage
3.3. DNA Damaging Agents
3.3.1. Endogenous DNA Damaging Agents
3.3.2. Exogenous DNA Damaging Agents
3.3.3. Other DNA Damaging Agents
3.4. DNA Damage Response System
3.4.1. Key Components of DNA Repair System
3.5. Types of DNA Repair Systems
3.5.1. Direct Repair
3.5.2. Excision Repair
3.5.3. Indirect Repair
3.6. Mutations in DNA Repair Genes

4 INTRODUCTION TO SYNTHETIC LETHALITY
4.1. Chapter Overview
4.2. Concept of Synthetic Lethality
4.2.1. Historical Evolution of Synthetic Lethality
4.2.2. HRR and Synthetic Lethality
4.2.3. Other Synthetic Lethal Gene Interactions
4.2.4. Gene Interactions beyond Synthetic Lethality
4.2.5. Applications of Synthetic Lethality
4.2.6. Limitations of Synthetic Lethality
4.3. Identification of Synlet Interactions
4.3.1. Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR) Based Synlet Target Identification
4.3.2. RNA Interference (RNAi) Based Synlet Target Identification
4.3.3. Other Screening Platforms for Synlet Target Identification
4.4. Prevalent Trends Related to Synthetic Lethality
4.4.1. Recent News on Google: Emerging Focus Areas
4.4.2. Google Trends Analysis: Historical Timeline
4.4.3. Google Trends Analysis: Geographical Activity
4.4.4. Google Trends Analysis: Co-Relation with Other Therapeutic Areas
4.5 Concluding Remarks

5 MARKET OVERVIEW
5.1. Chapter Overview
5.2. Synthetic Lethality-based Drugs: Marketed and Development Pipeline
5.2.1. Analysis by Phase of Development
5.2.2. Analysis by Type of Molecule
5.2.3. Analysis by Type of Therapy
5.2.4. Analysis by Type of Synlet Target
5.2.5. Analysis by Type of Patient Segment
5.2.6. Analysis by Therapeutic Area
5.2.7. Analysis by Target Indication
5.2.8. Analysis by Route of Administration
5.3. Synthetic Lethality-based Drugs: List of Drug Developers
5.3.1. Analysis by Year of Establishment
5.3.2. Analysis by Location of Headquarters
5.3.3. Analysis by Company Size
5.3.4. Analysis by Company Size and Location of Headquarters

6 COMPANY PROFILES
6.1. Chapter Overview
6.2. Profiles of Established Players
6.2.1. AbbVie
6.2.2. AstraZeneca
6.2.3. BeiGene
6.2.4. Clovis Oncology
6.2.5. GlaxoSmithKline
6.2.6. Pfizer
6.3. Profiles of Small and Mid-Sized Players
6.3.1. AtlasMedx
6.3.2. Chordia Therapeutics
6.3.3. IDEAYA Biosciences
6.3.4. Mission Therapeutics
6.3.5. Repare Therapeutics
6.3.6. Sierra Oncology
6.3.7. SyntheX Labs

7 EMERGING TRENDS ON SOCIAL MEDIA
7.1. Chapter Overview
7.2. Scope and Methodology
7.3. Synthetic Lethality: Trends on Twitter
7.3.1. Cumulative Year-Wise Activity
7.3.2. Historical Trends in Volume of Tweets
7.3.3. Evolutionary Trend Analysis
7.3.4. Trending Words / Phrases on Twitter
7.3.5. Most Prolific Contributors on Twitter
7.3.6. Most Popular Synlet Targets / Patient Mutations on Twitter
7.3.7. Most Popular Indications on Twitter
7.3.8. Heat Map Analysis: Distribution by Synlet Targets / Patient Mutations and Indications
7.4. Most Popular Tweets
7.5. Concluding Remarks

8 PUBLICATION ANALYSIS
8.1. Chapter Overview
8.2. Scope and Methodology
8.3. Synthetic Lethality: List of Recent Publications, 2019
8.3.1. Analysis by Type of Publication
8.3.2. Analysis by Study Objective
8.4. Synthetic Lethality: Publication Analysis, 2017-2019
8.4.1. Analysis by Year of Publication
8.4.2. Emerging Focus Areas
8.4.3. Analysis by Synlet Targets / Patient Mutations
8.4.3.1. Most Popular Synlet Targets / Patient Mutations
8.4.3.2. Year-Wise Trend in Activity for Popular Synlet Targets / Patient Mutations
8.4.4. Analysis by Target Indications
8.4.4.1. Most Popular Target Indications
8.4.4.2. Year-Wise Trend in Activity for Popular Target Indications
8.4.5. Analysis by Key Research Journals
8.4.5.1. Key Journals Based on Number of Publications
8.4.5.2. Analysis by Journal Impact Factor
8.4.5.3. Key Journals Based on Journal Impact Factor
8.4.6. Key Research Hubs
8.4.7. Most Popular Authors
8.4.8. Analysis of Publications with Grant Support
8.4.8.1. Most Popular Grant Bodies
8.4.8.2. Location of Grant Bodies
8.5. Publication Benchmark Analysis

9 ABSTRACT ANALYSIS
9.1. Chapter Overview
9.2. Scope and Methodology
9.3. Synthetic Lethality: List of American Society of Clinical Oncology Abstracts
9.3.1. Analysis by Year of Publication
9.3.2. Emerging Focus Areas
9.3.3. Most Popular Drugs
9.3.4. Most Popular Synlet Targets / Patient Mutations
9.3.5. Most Popular Target Indications
9.3.6. Most Popular Principal Authors
9.3.6.1. Analysis by Locations of Principal Authors
9.4.6.2. Analysis by Industry Type of Principal Authors
9.4.6.3. Analysis by Active Organization
9.4.6.4. Analysis by Author Designation
9.4.6.5. Most Popular Authors

10 ACADEMIC GRANTS ANALYSIS
10.1. Chapter Overview
10.2. Scope and Methodology
10.3. Synthetic Lethality: List of Grants Awarded by National Institutes of Health
10.4. Grant Attractiveness Analysis

11 FUNDING AND INVESTMENT ANALYSIS
11.1. Chapter Overview
11.2. Types of Funding
11.3. Synthetic Lethality: List of Funding and Investments
11.4. Concluding Remarks

12 TARGET BENCHMARK ANALYSIS
12.1. Chapter Overview
12.2. Scope and Methodology
12.3. Target Benchmark Analysis
12.3.1. Clinically Validated Synlet Targets
12.3.2. Preclinically Validated Synlet Targets
12.3.3. Early Stage Research Validated Synlet Targets
12.4. Initiatives of Big Pharmaceutical Players
12.5. Concluding Remarks

13 ROLE OF COMPANION DIAGNOSTICS IN SYNTHETIC LETHALITY
13.1. Chapter Overview
13.2. Concept of Companion Diagnostics
13.3. Development of Companion Diagnostics
13.4. Advantages of Companion Diagnostics
13.5. Applications of Companion Diagnostics in Synthetic Lethality
13.6. Companion Diagnostics: List of Available / Under Development Tests
13.6.1. Analysis by Synlet Target
13.6.2. Analysis by Type of Biomarker
13.6.3. Analysis by Type of Biomarker and Technology
13.6.4. Analysis by Target Indication
13.6.5. Analysis by Developer and Synlet Target
13.6.6. Most Prominent Developers
13.7. Case-in-Point: Companion Diagnostics for Commercially Available Poly-ADP Ribose Polymerase (PARP) Inhibitors
13.7.1. Companion Diagnostics Test for Niraparib
13.7.2. Companion Diagnostics Test for Olaparib
13.7.3. Companion Diagnostics Test for Rucaparib
13.7.4. Companion Diagnostics Test for Talazoparib
13.8. Future Perspective

14 MARKET FORECAST
14.1. Chapter Overview
14.2. Scope and Limitations
14.3. Forecast Methodology and Key Assumptions
14.4. Overall Synthetic Lethality-based Drugs Market, 2019-2030
14.4.1. Synthetic Lethality-based Drugs Market: Distribution by Type of Molecule, 2019-2030
14.4.2. Synthetic Lethality-based Drugs Market: Distribution by Synlet Target, 2019-2030
14.4.3. Synthetic Lethality-based Drugs Market: Distribution by Target Indication, 2019-2030
14.4.4. Synthetic Lethality-based Drugs Market: Distribution by Route of Administration, 2019-2030
14.4.5. Synthetic Lethality-based Drugs Market: Distribution by Geography, 2019-2030
14.4.6. Product-wise Sales Forecast
14.4.6.1 Niraparib (GlaxoSmithKline)
14.4.6.2. Olaparib (AstraZeneca)
14.4.6.3. Rucaparib (Clovis Oncology)
14.4.6.4. Talazoparib (Pfizer)
14.4.6.5. Pamiparib (BeiGene)
14.4.6.6. Veliparib (AbbVie)
14.4.6.7. Adavosertib (AstraZeneca)
14.4.6.8. AZD6738 (AstraZeneca)
14.4.6.9. APX3330 (Apexian Pharmaceuticals)
14.4.6.10. CB-839 (Calithera Biosciences)
14.4.6.11. CX-5461 (Senhwa Biosciences)
14.4.6.12. LB-100 (Lixte Biotechnology)
14.4.6.13. SRA737-01 (Sierra Oncology)
14.4.6.14. SRA737-02 (Sierra Oncology)
14.4.7. Concluding Remarks

15 CONCLUDING REMARKS

16 EXECUTIVE INSIGHTS
16.1. Chapter Overview
16.2. Artios Pharma
16.3. IMPACT Therapeutics
16.4. Harvard Medical School
16.5. Panjab University
16.6. UbiQ

17 APPENDIX 1: TABULATED DATA

18 APPENDIX 2: LIST OF COMPANIES AND ORGANIZATIONS

For more information about this report visit https://www.researchandmarkets.com/r/5qngnu

Research and Markets also offers Custom Research services providing focused, comprehensive and tailored research.

Media Contact:

Research and Markets
Laura Wood, Senior Manager
press@researchandmarkets.com

For E.S.T Office Hours Call +1-917-300-0470
For U.S./CAN Toll Free Call +1-800-526-8630
For GMT Office Hours Call +353-1-416-8900

U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716

View original content:http://www.prnewswire.com/news-releases/synthetic-lethality-based-drugs-and-targets-market-2030-300927550.html

SOURCE Research and Markets